Market Cap | 177.08M | P/E | - | EPS this Y | 81.30% | Ern Qtrly Grth | - |
Income | -204.1M | Forward P/E | -1.56 | EPS next Y | 58.10% | 50D Avg Chg | -12.00% |
Sales | 36.58M | PEG | - | EPS past 5Y | - | 200D Avg Chg | -56.00% |
Dividend | N/A | Price/Book | 0.76 | EPS next 5Y | - | 52W High Chg | -87.00% |
Recommedations | 2.50 | Quick Ratio | 0.68 | Shares Outstanding | 86M | 52W Low Chg | 5.00% |
Insider Own | 0.12% | ROA | -32.64% | Shares Float | 80.79M | Beta | 2.33 |
Inst Own | 11.76% | ROE | -138.33% | Shares Shorted/Prior | 4.16M/4.23M | Price | 0.58 |
Gross Margin | 28.97% | Profit Margin | - | Avg. Volume | 10,140,433 | Target Price | 1.90 |
Oper. Margin | -203.36% | Earnings Date | Nov 6 | Volume | 9,837,460 | Change | -5.08% |
Bionano Genomics, Inc. provides genome analysis software that enables genomics labs to analyze and interpret data across a range of platforms to generate informative data visualizations for streamlined and simple reporting of causal variants. It offers Saphyr, a sample-to-result solution for structural variation analysis by optical genome mapping for genome analysis and understanding of genetic variation and function; Saphyr instrument, a single-molecule imager; Saphyr Chip, a consumable that packages the nanochannel arrays for DNA linearization; and Bionano Prep Kits and DNA labeling kits, which provide the reagents and protocols for extracting and labeling ultra-high molecular weight DNA. The company also provides Saphyr and Bionano compute servers; and VIA software, which offers one system for analysis and interpretation of genomic variants from microarray and next-generation sequencing data for cytogenetics and molecular genetics. In addition, it offers testing and laboratory services comprising FirstStepDx PLUS, a chromosomal microarray for identifying an underlying genetic cause in individuals with autism spectrum disorder, developmental delay, and intellectual disability; Fragile X syndrome (FXS) testing services; NextStepDx PLUS, a exome sequencing test to identify genetic variants that are associated with disorders of childhood development; OGM-Dx HemeOne testing; OGM-Dx FSHD, a test for individuals suspected of having FSHD type 1; and OGM-Dx Postnatal Whole Genome SV and OGM-Dx Prenatal Whole Genome SV for comprehensive testing. Bionano Genomics, Inc. was founded in 2003 and is headquartered in San Diego, California.
BTIG | Buy | May 16, 24 |
Scotiabank | Sector Outperform | Mar 7, 24 |
Maxim Group | Hold | Nov 13, 23 |
BTIG | Buy | Aug 10, 23 |
Insider Trades | Relationship | Date | Transactions | Cost($) | #Shares | Value($) | #Share Own | SEC Form 4 |
---|---|---|---|---|---|---|---|---|
Mamuszka Hannah | Director Director | Jun 13 | Buy | 0.76 | 65,789 | 50,000 | 65,789 | 06/14/23 |
Holmlin R. Erik | President and CEO President and CEO | May 16 | Buy | 0.6426 | 15,000 | 9,639 | 806,474 | 05/16/23 |
Stewart Christopher P. | Chief Financial Offi.. Chief Financial Officer | May 12 | Buy | 0.6683 | 50,000 | 33,415 | 281,373 | 05/16/23 |
Linney Yvonne | Director Director | Aug 15 | Option | 0.38 | 20,000 | 7,600 | 20,000 | 08/17/22 |
Linney Yvonne | Director Director | Aug 15 | Sell | 3.62 | 20,000 | 72,400 | 08/17/22 | |
BARKER DAVID L | Director Director | Jul 07 | Option | 0.51 | 44,470 | 22,680 | 58,364 | 07/11/22 |
Stewart Christopher P. | Chief Financial Offi.. Chief Financial Officer | May 13 | Option | 0.56 | 60,000 | 33,600 | 121,579 | 05/16/22 |
Holmlin R. Erik | President and CEO President and CEO | Nov 29 | Buy | 3.99 | 5,025 | 20,050 | 5,025 | 12/01/21 |